Curis, Inc. and Genentech have filed an IND application with the FDA to initiate Phase I testing of a systemically administered small molecule Hedgehog antagonist for the treatment of cancer. Under the terms of the June 2003 collaboration agreement, Genentech will pay Curis $3 million cash after filing the IND application. Should this small molecule drug candidate progress successfully through development and gain regulatory approval, Curis will be eligible to receive additional cash payment...